Information Provided By: 
Fly News Breaks for May 19, 2015
BLUE
May 19, 2015 | 12:51 EDT
Wedbush analyst David Nierengarten raised his price target for shares of bluebird bio to $222 from $146 after the company laid out accelerated development paths for LentiGlobin in beta-thal. Nierengarten views the regulatory feedback bluebird received in both the U.S. and Europe as favorable and reflecting the "many benefits" of LentiGlobin therapy. He keeps an Outperform rating on the stock. Shares of bluebird are up $7.42 to $163.82 in afternoon trading.
News For BLUE From the Last 2 Days
There are no results for your query BLUE
